ArticleCancers2020
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 55 citations in OpenAlex.
- Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).Breast cancer research : BCR · 2023Trial
- The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology.Nature reviews. Clinical oncology · 2026Review
- HER2 expression in breast cancer: evidence gaps and challenges.NPJ precision oncology · 2025Review
- Enhancing HER2-low breast cancer detection with quantitative transcriptomics.NPJ breast cancer · 2025Article
- HER2DX ERBB2 score in advanced HER2-positive gastric cancer treated with trastuzumab and chemotherapy.ESMO open · 2025Article
- RNA sequencing and immunohistochemistry jointly improve tumor biomarker interpretation.Scientific reports · 2025Article
- Paclitaxel-related type I Kounis Syndrome in a very young patient with HER2-positive breast cancer and the role of genomics to disentangle a complex therapeutic scenario: a case report and narrative review.Breast (Edinburgh, Scotland) · 2025Review
- Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance.Nature reviews. Clinical oncology · 2024Review
- Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.Nature communications · 2024Article
- Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer.Breast cancer research : BCR · 2024Article
- Case report: Near-complete response to neratinib-based treatment in HR-positiveFrontiers in oncology · 2024Article
- An Analysis of Clinical and Pathologic Features, RecurIndex Genomic Profiles, and Survival Outcomes in HER2-Low Breast Cancer.The oncologist · 2023Article
- Predicting Response to Antibody Drug Conjugates: A Focus on Antigens' Targetability.The oncologist · 2023Article
- RE: HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.Journal of the National Cancer Institute · 2023Article
- Reply to Bertucci, De Nonneville, and Finetti.Journal of the National Cancer Institute · 2023Article
- HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.Journal of the National Cancer Institute · 2023Article
- The HER2-low revolution in breast oncology: steps forward and emerging challenges.Therapeutic advances in medical oncology · 2023Review
- HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer.Cancers · 2022Article
- Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer.Science advances · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 7 institutions in 3 countries.
Gaia GriguoloDivision of Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, 35128 Padova, Italy.ORCID 0000-0002-8782-4509
Fara Brasó-MaristanyDepartment of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Blanca González-FarréTranslational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain.
Tomás PascualDepartment of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.ORCID 0000-0001-8431-3183
Núria ChicDepartment of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Tamara SauríDepartment of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Ronald KatesThe West German Study Group, 41061 Mönchengladbach, Germany.
Oleg GluzThe West German Study Group, 41061 Mönchengladbach, Germany.
Débora MartínezDepartment of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Laia ParéSOLTI breast cancer cooperative group, 08008 Barcelona, Spain.
Vassilena TsvetkovaDepartment of Surgery, Oncology and Gastroenterology, University of Padova, 35124 Padova, Italy.
David PesantezDepartment of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Maria VidalDepartment of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Barbara AdamoDepartment of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Montserrat MuñozDepartment of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Patricia GalvánDepartment of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Laura BarberáDepartment of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Miriam CuatrecasasDepartment of Pathology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.ORCID 0000-0003-3063-0110
Mathias ChristgenMedical School Hannover, Institute of Pathology, 30625 Hannover, Germany.
Hans KreipeMedical School Hannover, Institute of Pathology, 30625 Hannover, Germany.
Inés Monge-EscartínPharmacy Department, Division of Medicines, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Patricia VillagrasaSOLTI breast cancer cooperative group, 08008 Barcelona, Spain.
Dolors SoyPharmacy Department, Division of Medicines, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.ORCID 0000-0001-8128-345X
Tommaso GiarratanoDivision of Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, 35128 Padova, Italy.
Maria Vittoria DieciDivision of Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, 35128 Padova, Italy.ORCID 0000-0002-3967-9861
Pierfranco ConteDivision of Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, 35128 Padova, Italy.ORCID 0000-0002-5210-5344
Nadia HarbeckBreast Center, Department of Gynecology and Obstetrics, University of Munich (LMU) and CCCLMU, 80337 Munich, Germany.
Valentina GuarneriDivision of Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, 35128 Padova, Italy.
Aleix PratDepartment of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.ORCID 0000-0003-2377-540X
Hospital Clínic de Barcelona · ESUniversity of Padua · ITMedizinische Hochschule Hannover · DEDeutsches Archäologisches Institut, Zentrale · DEIstituto Oncologico Veneto · ITLudwig-Maximilians-Universität München · DEUniversity of Cologne · DE
Funding
Asociación Española Contra el Cáncer AECC_Postdoctoral17-1062Breast Cancer Now 2018NOVPCC1294Breast Cancer Research Foundation 19-20-26-PRATConquer Cancer Foundation/Shanken Family Foundation YIA in Breast Cancer 2019DiSCOG - University of Padova DOR 1721185/17DiSCOG - University of Padova DOR 1830512/18Fundació La Marató TV3 201935-30Generalitat de Catalunya Peris PhD4MD 2019 SLT008/18/00122Horizon 2020 Framework Programme H2020-SC1-BHC-2018-2020Instituto de Salud Carlos III PI16/00904 and PI19/01846
Abstract
Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that the heterogeneity in the response seen in patients is partly explained by the levels of human epidermal growth factor receptor 2 gene
Indexed as
antibody-drug conjugatesERBB2 mRNAHER2-positive breast cancerT-DM1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.